Investor Relations

Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

View all »   RSSRecent Releases

Feb 9, 2017
Arbutus to Participate in Upcoming Investor Conferences

Feb 8, 2017
Arbutus Is Granted a Pre-trial Injunction Restraining Acuitas From Entering Into Agreements Sublicensing Arbutus LNP Technology


View all »Events & Presentations

Feb 22, 2017
RBC Capital Markets 2017 Global Healthcare Conference

Feb 16, 2017
LEERINK Partners 6th Annual Global Healthcare Conference